Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Qualigen Therapeutics, Inc. (RTTR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"QUALIGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS For the Three Months Ended June 30, For the Six Months Ended June 30, 2023 2022 2023 2022 REVENUES Net product sales $ 1,627,031 $ 1,430,534 $ 3,234,201 $ 2,152,563 Total revenues 1,627,031 1,430,534 3,234,201 2,152,563 EXPENSES Cost of product sales 1,016,542 1,099,677 2,281,368 1,928,524 General and administrative 2,665,849 2,660,857 4,380,283 5,559,608 Research and development 1,326,544 1,506,227 3,448,095 3,370,972 Sales and marketing 169,223 305,103 368,337 443,426 Total expenses 5,178,158 5,571,864 10,478,083 11,302,530 LOSS FROM OPERATIONS OTHER EXPENSE , NET Gain on change in fair value of warrant liabilities Interest expense , net 377,416 921,652 Loss on voluntary conversio..." |
|
| 08/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/05/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/10/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex Transcription Inhibitor for the Intended Indication of Pancreatic Cancer CARLSBAD, Calif., January 10, 2023 — Qualigen Therapeutics, Inc. , a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead drug candidate, QN-302, for the indication of Pancreatic Cancer. QN-302 is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells." |
|
| 12/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT qualigen therapeutics, inc. Warrant Shares: 2,500,000 Initial Exercise Date: June 22, 2023 Issue Date: December 22, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, Alpha Capital Anstalt or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of the Issue Date and on or prior to 5:00 p.m. on June 22, 2028 but not thereafter, to subscribe for and purchase from Qualigen Therapeutics, Inc., a Delaware corporation , up to 2,500,000 shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitaliz...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December 21, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: AR...",
"8% SENIOR CONVERTIBLE DEBENTURE DUE DECEMBER 22, 2025 THIS 8% SENIOR CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 8% Senior Convertible Debentures of Qualigen Therapeutics, Inc., a Delaware corporation , having its principal place of business at 2042 Corte de Nogal, Carlsbad, CA 92011, designated as its 8% Senior Convertible Debenture due December 22, 2025 . FOR VALUE RECEIVED, the Company promises to pay to Alpha Capital Anstalt or its registered assigns , or shall have paid pursuant to the terms hereunder, the principal sum of $3,300,000 on December 22, 2025 or such earlier date as this Debenture is required or permitted to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amoun...",
"Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:" |
|
| 12/12/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/22/2022 |
8-K
| Quarterly results |
| 10/28/2022 |
8-K
| Quarterly results |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/02/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 08/26/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 08/16/2022 |
8-K
| Quarterly results |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 03/04/2022 |
8-K
| Quarterly results |
| 01/18/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 12/17/2021 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 12/10/2021 |
8-K
| Quarterly results |
| 12/01/2021 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Stradling Yocca Carlson & Rauth, P.C.",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 29, 2021, between Qualigen Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the...",
"PLACEMENT AGENCY AGREEMENT Qualigen Therapeutics, Inc. 2042 Corte Del Nogal Carlsbad, California 92011 Attn: Michael S. Poirier President and Chief Executive Officer",
"WAIVER AND AMENDMENT",
"Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering" |
|
| 08/13/2021 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Amendments to Articles of Incorpo... |
| 05/17/2021 |
8-K
| Quarterly results |
| 04/09/2021 |
8-K
| Quarterly results |
| 03/05/2021 |
8-K
| Quarterly results |
| 01/06/2021 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
| 12/18/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Opinion of Stradling Yocca Carlson & Rauth, a Professional Corporation",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of December 16, 2020, between Qualigen Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act of 1933, as amended , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the...",
"Placement Agency Agreement between Qualigen Therapeutics, Inc. and A.G.P./Alliance Global Partners",
"“Two-Year” Common Stock Purchase Warrant for 1,348,314 shares",
"“Deferred” Common Stock Purchase Warrant for 842,696 shares",
"“Prefunded” Common Stock Purchase Warrant for 1,000,000 shares",
"Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering" |
|
|
|
|